Related Experiment Video
Updated: Jan 20, 2026
Isolation of Murine Peritoneal Macrophages to Carry Out Gene Expression Analysis Upon Toll-like Receptors Stimulation
Published on: April 29, 2015
Hepcidin
1The Ohio State University, Wexner Medical Center, Columbus, OH.
Insights
Iron metabolism dysregulation causes anemia in chronic kidney disease (CKD). Hepcidin, a key iron regulator, offers new therapeutic targets for treating anemia of CKD.
Area of Science:
- Nephrology
- Hematology
- Metabolic Disorders
Background:
- Anemia is common in chronic kidney disease (CKD), often linked to iron metabolism issues.
- Current markers for iron status are imperfect, leading to misdiagnosis and poor treatment outcomes for anemia.
- Hepcidin, a liver-produced peptide, is a critical regulator of iron homeostasis.
Purpose of the Study:
- To explore the role of hepcidin in the development and treatment of anemia of CKD.
- To highlight the limitations of current iron status markers in CKD anemia.
- To discuss the therapeutic potential of modulating hepcidin for anemia of CKD.
Main Methods:
- Review of scientific literature on iron metabolism, hepcidin, and anemia of CKD.
- Analysis of hepcidin's regulatory mechanisms (iron supply, erythropoiesis, inflammation).
- Examination of the impact of altered hepcidin levels on iron status and erythropoiesis.
Main Results:
- Hepcidin dysregulation is central to iron deficiency and overload in CKD anemia.
- Hepcidin levels are influenced by iron availability, erythropoietic demand, and inflammation.
- Altered hepcidin is linked to impaired red blood cell production and anemia.
Conclusions:
- Understanding hepcidin's role provides crucial insights into hematologic disorders like CKD anemia.
- Targeting hepcidin pathways with agonists or antagonists presents promising therapeutic strategies.
- Development of hepcidin-modulating agents offers future treatment potential for anemia of CKD.
Abstract:
Dysregulation of metabolism and utilization of iron can lead to the development and maintenance of anemia of CKD. Anemia is prevalent among patients with CKD. The markers of iron sufficiency or availability of iron are far from perfect which results in inaccurate diagnosis and treatment of anemia with poor outcomes. Hepcidin, a 25 amino acid peptide produced by the hepatocytes, has emerged as the key regulator of uptake and release of iron in the tissues to maintain a steady supply of iron to erythron and other tissues while avoiding higher levels of iron that could be detrimental to the organs. Hepcidin itself is regulated by the supply of iron, the need for erythropoiesis, and the state of inflammation. Alterations in hepcidin levels are associated with restricted erythropoiesis, anemia, and iron overload. Discovery of hepcidin and elucidation of its mechanism of action and consequences of its upregulation and suppression have unraveled important insight into many hematologic disorders including anemia of CKD. This knowledge has also unlocked unique opportunities to modulate hepcidin via agonists and antagonists of hepcidin and its feedback pathways to treat clinical conditions. Many such agents are being developed and have potential therapeutic utility in future.
Related Concept Videos
08:21Isolation of Murine Peritoneal Macrophages to Carry Out Gene Expression Analysis Upon Toll-like Receptors Stimulation
05:08Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
04:46Assessment of Leishmania Virulence within Cultured Macrophages